The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
K Philipp - One of the best experts on this subject based on the ideXlab platform.
-
comparison between three dimensional placental volume at 12 weeks and uterine artery impedance notching at 22 weeks in screening for pregnancy induced hypertension pre eclampsia and fetal growth restriction in a Low Risk Population
Ultrasound in Obstetrics & Gynecology, 2006Co-Authors: E Hafner, K Schuchter, M Metzenbauer, D Hofinger, F Stonek, T Waldhor, K PhilippAbstract:Objectives To compare the value of three-dimensional placental volume at 12 weeks and uterine artery Doppler at 22 weeks for predicting pregnancy-induced hypertension (PIH), pre-eclampsia and fetal growth restriction in a Low-Risk Population. Methods Over a 20-month period we calculated the placental quotient (PQ = placental volume/crown–rump length) at 11–13 weeks' gestation in all women with singleton pregnancies who booked for delivery in our hospital. At 22 weeks, in the same Population, we calculated the mean pulsatility index (PI) of both uterine arteries and the presence of an early diastolic notch was noted. Logistic regression models, the PQ and Doppler parameters were used to compare the two screening methods for subgroups of pregnancy outcome. Results Complete outcome data were obtained in 2489 consecutive singleton pregnancies. Logistic regression models for the detection of pre-eclampsia had a sensitivity of 38.5% (PQ) vs. 44.8% (Doppler); for the detection of small-for-gestational age (SGA) the sensitivity was 27.1% (PQ) vs. 28.1% (Doppler) at a specificity of 90%. Taking a PQ of ≤ 10th centile, a mean uterine PI of ≥ 90th centile and a bilateral notch, the sensitivity for detection of SGA was 25.0%, 20.2% and 22.0%, respectively; for PIH it was 9.5%, 4.8% and 4.8%; for pre-eclampsia without SGA it was 20.0%, 28%, 12%; for PIH/pre-eclampsia with SGA it was 30.8%, 46.1% and 69.2%. In the group with the most severe complications, in which delivery took place before 34 weeks, the sensitivity was 50.0%, 50.0% and 38.9%, respectively. Conclusions PQ at 12 weeks and uterine artery Doppler at 22 weeks have similar sensitivities for predicting pre-eclampsia and fetal growth restriction, although uterine artery Doppler is marginally more sensitive for the prediction of pre-eclampsia. While both methods are insufficient for screening in a Low-Risk Population, the PQ method has the potential advantage of being performed in the first trimester. Copyright © 2006 ISUOG. Published by John Wiley & Sons, Ltd.
-
sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a Low Risk Population
Ultrasound in Obstetrics & Gynecology, 2001Co-Authors: K Schuchter, Günther Stangl, Egon Ogris, Erich Hafner, K PhilippAbstract:Objective To evaluate screening for trisomy 21 in a Low-Risk Population utilizing a combination of nuchal translucency measurement in the first trimester and the triple test in the second trimester. Methods This was a retrospective study of 9342 women with singleton pregnancies who booked for delivery in our hospital over a period of 5 years. A nuchal translucency scan was carried out at 10–13 weeks' gestation and for those with a measurement of 3.5 mm or more chorionic villus sampling was performed. All other women were asked to return for the triple test at 16 weeks' gestation. Amniocentesis was offered to women in whom the nuchal translucency was 2.5–3.4 mm, the triple test showed a Risk of ≥ 1: 250 and in women aged ≥ 35 years. Results The detection rate using the combined screening method was 95% (18/19) with a screen-positive rate of 7.2%. In comparison, screening by maternal age alone would have identified nine (47%) trisomy 21 pregnancies with a screen-positive rate of 10.7%. Conclusion Our data suggest that the combination of nuchal translucency measurement in the first trimester and the triple test in the second trimester is associated with a very high detection rate of trisomy 21 at a relatively Low screen-positive rate. Copyright © 2001 International Society of Ultrasound in Obstetrics and Gynecology
-
results of routine fetal nuchal translucency measurement at weeks 10 13 in 4233 unselected pregnant women
Prenatal Diagnosis, 1998Co-Authors: Erich Hafner, K Schuchter, Eva Liebhart, K PhilippAbstract:The aim of this study was to determine the value of nuchal translucency (NT) measurement for the detection of aneuploidies and other malformations in a Low-Risk Population. In total, 4233 women who booked in our hospital for delivery were examined between the tenth and 13th week of gestation. Of the 17 chromosomal abnormalities that occurred, 11 were detected using the measurement of NT (65 per cent). Only three of the seven Down syndrome pregnancies were detected using this technique (43 per cent). The remaining four Down syndrome babies were diagnosed either because of positive biochemical testing or by amniocentesis because of maternal age. A total of 69 serious malformations including chromosomal defects were detected during the study period. In 18 of these cases, the NT measurement was ⩾2·5 mm (26 per cent). Most of the malformations without aneuploidies were of cardiac origin. The data show that the NT measurement is a valuable marker for aneuploidy even in a Low Risk-Population. It is also of value in the diagnosis of other serious malformations, particularly cardiac defects. © 1998 John Wiley & Sons, Ltd.
K Schuchter - One of the best experts on this subject based on the ideXlab platform.
-
comparison between three dimensional placental volume at 12 weeks and uterine artery impedance notching at 22 weeks in screening for pregnancy induced hypertension pre eclampsia and fetal growth restriction in a Low Risk Population
Ultrasound in Obstetrics & Gynecology, 2006Co-Authors: E Hafner, K Schuchter, M Metzenbauer, D Hofinger, F Stonek, T Waldhor, K PhilippAbstract:Objectives To compare the value of three-dimensional placental volume at 12 weeks and uterine artery Doppler at 22 weeks for predicting pregnancy-induced hypertension (PIH), pre-eclampsia and fetal growth restriction in a Low-Risk Population. Methods Over a 20-month period we calculated the placental quotient (PQ = placental volume/crown–rump length) at 11–13 weeks' gestation in all women with singleton pregnancies who booked for delivery in our hospital. At 22 weeks, in the same Population, we calculated the mean pulsatility index (PI) of both uterine arteries and the presence of an early diastolic notch was noted. Logistic regression models, the PQ and Doppler parameters were used to compare the two screening methods for subgroups of pregnancy outcome. Results Complete outcome data were obtained in 2489 consecutive singleton pregnancies. Logistic regression models for the detection of pre-eclampsia had a sensitivity of 38.5% (PQ) vs. 44.8% (Doppler); for the detection of small-for-gestational age (SGA) the sensitivity was 27.1% (PQ) vs. 28.1% (Doppler) at a specificity of 90%. Taking a PQ of ≤ 10th centile, a mean uterine PI of ≥ 90th centile and a bilateral notch, the sensitivity for detection of SGA was 25.0%, 20.2% and 22.0%, respectively; for PIH it was 9.5%, 4.8% and 4.8%; for pre-eclampsia without SGA it was 20.0%, 28%, 12%; for PIH/pre-eclampsia with SGA it was 30.8%, 46.1% and 69.2%. In the group with the most severe complications, in which delivery took place before 34 weeks, the sensitivity was 50.0%, 50.0% and 38.9%, respectively. Conclusions PQ at 12 weeks and uterine artery Doppler at 22 weeks have similar sensitivities for predicting pre-eclampsia and fetal growth restriction, although uterine artery Doppler is marginally more sensitive for the prediction of pre-eclampsia. While both methods are insufficient for screening in a Low-Risk Population, the PQ method has the potential advantage of being performed in the first trimester. Copyright © 2006 ISUOG. Published by John Wiley & Sons, Ltd.
-
sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a Low Risk Population
Ultrasound in Obstetrics & Gynecology, 2001Co-Authors: K Schuchter, Günther Stangl, Egon Ogris, Erich Hafner, K PhilippAbstract:Objective To evaluate screening for trisomy 21 in a Low-Risk Population utilizing a combination of nuchal translucency measurement in the first trimester and the triple test in the second trimester. Methods This was a retrospective study of 9342 women with singleton pregnancies who booked for delivery in our hospital over a period of 5 years. A nuchal translucency scan was carried out at 10–13 weeks' gestation and for those with a measurement of 3.5 mm or more chorionic villus sampling was performed. All other women were asked to return for the triple test at 16 weeks' gestation. Amniocentesis was offered to women in whom the nuchal translucency was 2.5–3.4 mm, the triple test showed a Risk of ≥ 1: 250 and in women aged ≥ 35 years. Results The detection rate using the combined screening method was 95% (18/19) with a screen-positive rate of 7.2%. In comparison, screening by maternal age alone would have identified nine (47%) trisomy 21 pregnancies with a screen-positive rate of 10.7%. Conclusion Our data suggest that the combination of nuchal translucency measurement in the first trimester and the triple test in the second trimester is associated with a very high detection rate of trisomy 21 at a relatively Low screen-positive rate. Copyright © 2001 International Society of Ultrasound in Obstetrics and Gynecology
-
results of routine fetal nuchal translucency measurement at weeks 10 13 in 4233 unselected pregnant women
Prenatal Diagnosis, 1998Co-Authors: Erich Hafner, K Schuchter, Eva Liebhart, K PhilippAbstract:The aim of this study was to determine the value of nuchal translucency (NT) measurement for the detection of aneuploidies and other malformations in a Low-Risk Population. In total, 4233 women who booked in our hospital for delivery were examined between the tenth and 13th week of gestation. Of the 17 chromosomal abnormalities that occurred, 11 were detected using the measurement of NT (65 per cent). Only three of the seven Down syndrome pregnancies were detected using this technique (43 per cent). The remaining four Down syndrome babies were diagnosed either because of positive biochemical testing or by amniocentesis because of maternal age. A total of 69 serious malformations including chromosomal defects were detected during the study period. In 18 of these cases, the NT measurement was ⩾2·5 mm (26 per cent). Most of the malformations without aneuploidies were of cardiac origin. The data show that the NT measurement is a valuable marker for aneuploidy even in a Low Risk-Population. It is also of value in the diagnosis of other serious malformations, particularly cardiac defects. © 1998 John Wiley & Sons, Ltd.
William A Grobman - One of the best experts on this subject based on the ideXlab platform.
-
the utility of uterine artery doppler velocimetry in prediction of preeclampsia in a Low Risk Population
Obstetric Anesthesia Digest, 2013Co-Authors: Leslie Myatt, Rebecca G Clifton, James M Roberts, Catherine Y Spong, John C Hauth, Michael W Varner, Ronald J Wapner, John M Thorp, Brian M Mercer, William A GrobmanAbstract:Objective The underlying pathophysiology of preeclampsia is thought to be abnormal trophoblast invasion of the spiral arteries, leading to maldevelopment of uteroplacental perfusion. We estimated whether uterine artery Doppler measurements made in the early second trimester would predict the subsequent development of preeclampsia.
-
serum levels of activin a and inhibin a and the subsequent development of preeclampsia
Obstetrics & Gynecology, 2000Co-Authors: William A Grobman, Eileen Y WangAbstract:Abstract Objective: To determine whether serum levels of activin A and inhibin A are altered in patients before development of preeclampsia. Methods: Blood samples were collected from patients during the second trimester of prenatal care. We identified patients who subsequently developed preeclampsia and matched them with patients who had no evidence of preeclampsia during their gestation. Matching criteria included gestational age at blood sampling, gestational age at delivery, and birth weight. Assays were then performed to assess the levels of activin A and inhibin A in the control and study groups. A power calculation determined that 12 patients who subsequently developed preeclampsia, if matched with controls in a 1:2 ratio, would alLow the detection of differences in analyte levels that were 60% as large as those previously reported between patients already diagnosed with preeclampsia and matched controls. Results: Twelve patients with preeclampsia were identified and matched with 24 controls. No differences in serum levels of activin A or inhibin A were detected between the two groups. Because of the significant overlap of analyte levels between the two groups, no cutpoint that would alLow identification of patients destined to become preeclamptic could be determined. Conclusion: These data suggest that activin A and inhibin A cannot be used as markers for later development of preeclampsia in a Low-Risk Population.
Sailesh Kumar - One of the best experts on this subject based on the ideXlab platform.
-
reference centiles for the middle cerebral artery and umbilical artery pulsatility index and cerebro placental ratio from a Low Risk Population a generalised additive model for location shape and scale gamlss approach
Journal of Maternal-fetal & Neonatal Medicine, 2019Co-Authors: Christopher Flatley, Sailesh Kumar, Ristan M GreerAbstract:Objective: The primary aim of this study was to create reference ranges for the fetal Middle Cerebral artery Pulsatility Index (MCA PI), Umbilical Artery Pulsatility Index (UA PI) and the Cerebro–P...
-
screening performance of placental growth factor for the prediction of Low birth weight and adverse intrapartum and neonatal outcomes in a term Low Risk Population
Fetal Diagnosis and Therapy, 2017Co-Authors: Larissa N Bligh, Ristan M Greer, Sailesh KumarAbstract:Fetuses who fail to reach their genetic growth potential are thought to have sub-optimal placental function. Low placental growth factor (PlGF) levels have been shown to be predictive of placentally mediated conditions, such as pre-eclampsia or fetal growth restriction. We investigated the screening performance of PlGF for the prediction of Low birth weight ( Maternal PlGF levels were measured fortnightly in a blinded, prospective, observational study from 36 weeks of pregnancy. Women and clinicians were blinded to PlGF results, and pregnancies were managed according to local policies and guidelines. Intrapartum and neonatal outcomes were recorded. PlGF was analysed for association with, and predictive capacity for, Low birth weight, caesarean section for intrapartum fetal compromise (CS-IFC) and adverse neonatal outcomes. A total of 438 women were included in the final analysis. Lower PlGF levels were associated with Low birth weight, CS-IFC and adverse neonatal outcome. For a false-positive rate of 10 and 20%, respectively, the corresponding sensitivities were 9.7-11.1% and 22.2-26.8%. As a sole predictor for Low birth weight, CS-IFC and adverse neonatal outcome, PlGF was poor as a test.
Erich Hafner - One of the best experts on this subject based on the ideXlab platform.
-
sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a Low Risk Population
Ultrasound in Obstetrics & Gynecology, 2001Co-Authors: K Schuchter, Günther Stangl, Egon Ogris, Erich Hafner, K PhilippAbstract:Objective To evaluate screening for trisomy 21 in a Low-Risk Population utilizing a combination of nuchal translucency measurement in the first trimester and the triple test in the second trimester. Methods This was a retrospective study of 9342 women with singleton pregnancies who booked for delivery in our hospital over a period of 5 years. A nuchal translucency scan was carried out at 10–13 weeks' gestation and for those with a measurement of 3.5 mm or more chorionic villus sampling was performed. All other women were asked to return for the triple test at 16 weeks' gestation. Amniocentesis was offered to women in whom the nuchal translucency was 2.5–3.4 mm, the triple test showed a Risk of ≥ 1: 250 and in women aged ≥ 35 years. Results The detection rate using the combined screening method was 95% (18/19) with a screen-positive rate of 7.2%. In comparison, screening by maternal age alone would have identified nine (47%) trisomy 21 pregnancies with a screen-positive rate of 10.7%. Conclusion Our data suggest that the combination of nuchal translucency measurement in the first trimester and the triple test in the second trimester is associated with a very high detection rate of trisomy 21 at a relatively Low screen-positive rate. Copyright © 2001 International Society of Ultrasound in Obstetrics and Gynecology
-
results of routine fetal nuchal translucency measurement at weeks 10 13 in 4233 unselected pregnant women
Prenatal Diagnosis, 1998Co-Authors: Erich Hafner, K Schuchter, Eva Liebhart, K PhilippAbstract:The aim of this study was to determine the value of nuchal translucency (NT) measurement for the detection of aneuploidies and other malformations in a Low-Risk Population. In total, 4233 women who booked in our hospital for delivery were examined between the tenth and 13th week of gestation. Of the 17 chromosomal abnormalities that occurred, 11 were detected using the measurement of NT (65 per cent). Only three of the seven Down syndrome pregnancies were detected using this technique (43 per cent). The remaining four Down syndrome babies were diagnosed either because of positive biochemical testing or by amniocentesis because of maternal age. A total of 69 serious malformations including chromosomal defects were detected during the study period. In 18 of these cases, the NT measurement was ⩾2·5 mm (26 per cent). Most of the malformations without aneuploidies were of cardiac origin. The data show that the NT measurement is a valuable marker for aneuploidy even in a Low Risk-Population. It is also of value in the diagnosis of other serious malformations, particularly cardiac defects. © 1998 John Wiley & Sons, Ltd.
